

## CASIRIVIMAB plus IMDEVIMAB solution for infusion (Ronapreve® ▼) for treating COVID-19

The Cheshire and Merseyside Area Prescribing Group does not recommend the prescribing of CASIRIVIMAB plus IMDEVIMAB solution for infusion (Ronapreve® ▼), for treating COVID-19 in accordance with NICE TA878.

**BLACK**

[NICE technology appraisal \(TA\) 878](#)<sup>[1]</sup> (published 29 March 2023, updated 05 April 2023) states that casirivimab plus imdevimab (Ronapreve®), is not recommended for treating acute COVID-19 in adults.<sup>[1]</sup>

NICE states that casirivimab plus imdevimab (Ronapreve®) is not recommended because it is unlikely to be effective at treating COVID-19 and it is not possible to reliably estimate its cost effectiveness. Also, other evidence suggests that it is highly uncertain that casirivimab plus imdevimab (Ronapreve®) is effective against Omicron variants of COVID-19.<sup>[1]</sup>

Clinicians should continue to follow national guidance, local pathways and local formulary choices for the treatment of COVID-19.

See separate [red statement](#) for the Cheshire and Merseyside APG recommendation for prescribing of nirmatrelvir plus ritonavir (Paxlovid®), sotrovimab (Xevudy® ▼), and tocilizumab (RoActemra® ▼) for treating COVID-19 in accordance with NICE TA878.

### References

1. National Institute for Health and Care Excellence. Technology Appraisal TA878; [Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19](#), updated 05 April 2023. Accessed 20 April 2023.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.